What You Should Know:
– The U.S. healthcare system is rapidly embracing AI, and NVIDIA is at the forefront of this transformation, providing powerful tools and collaborating with public sector institutions to accelerate research and improve patient care. At the NVIDIA AI Summit in Washington, D.C., the company showcased its latest innovations, including NVIDIA NIM and NIM Agent Blueprints, which are already making a significant impact in the public sector.
NVIDIA NIM and NIM Agent Blueprints: Accelerating AI Adoption
NVIDIA NIM is a collection of cloud-native microservices that simplify the deployment and execution of AI models. NIM Agent Blueprints provide pre-trained, customizable workflows for various applications, allowing researchers to quickly adopt and adapt state-of-the-art AI models.
Digital Health AI Agents to Address Healthcare Challenges
These technologies are being utilized by leading research institutions to address critical healthcare challenges:
- National Cancer Institute (NIH): Researchers are using NVIDIA MONAI and the VISTA-3D NIM foundation model to analyze medical images, specifically segmenting and annotating 3D CT scans for improved cancer detection and diagnosis.
- National Center for Advancing Translational Sciences (NCATS): Scientists are leveraging the NIM Agent Blueprint for generative AI-based virtual screening to accelerate drug discovery and reduce the time and cost of developing new therapeutics.
- Genetic and Rare Diseases Information Center (NCATS): The center is exploring the use of the PDF data extraction blueprint to develop AI tools that can extract insights from vast PDF databases, improving their ability to answer patient questions and advance research on rare diseases.
Benefits for Medical Researchers
NVIDIA NIM and NIM Agent Blueprints offer several advantages for medical researchers:
- Simplified AI Adoption: Pre-trained models and customizable workflows make it easier to integrate AI into research processes.
- Accelerated Research: Optimized AI models speed up analysis and discovery, leading to faster breakthroughs.
- Cost-Effectiveness: By conducting more research digitally, scientists can reduce the need for expensive and time-consuming lab experiments.
Collaborations Driving Innovation
NVIDIA is also collaborating with key partners to further expand access and accelerate AI adoption in healthcare:
- AWS: The NIM Agent Blueprint for virtual screening is available through AWS HealthOmics, enabling researchers to leverage cloud-based infrastructure for drug discovery.
- ConcertAI: This oncology AI technology company is integrating NIM microservices into its platform to enhance clinical trial design, patient matching, and clinical decision-making.
- Deloitte: This global systems integrator is bringing the NIM Agent Blueprint for virtual screening to its clients worldwide, facilitating the adoption of generative AI for drug discovery.